

Brainify.Al Is Accepted Into Merck Digital Sciences Studio Program

Brainify.AI announces its acceptance into the Merck Digital Sciences Studio, a collaboration between Merck, Merck GHI Fund, Northpond Ventures

NEW YORK CITY, NEW YORK, USA, November 28, 2023 / EINPresswire.com/ -- Brainify.Al, an innovator at the forefront of precision psychiatry, today announces its acceptance into the Merck Digital Sciences Studio (MDSS), a digital accelerator designed to enable the next generation of technologies for drug discovery and development, including artificial intelligence and machine learning. MDS Studio was founded to offer support for earlystage biomedical startups providing strategic guidance, direct investment and other resources.

Strategic Focus:

- Brainify.Al is dedicated to enhancing the accuracy and efficiency of psychiatry clinical trials.
- Its suite of Al-driven products, including Placebolnsight Al, and Therapylnsight Al, are designed to enable clinical development. Pioneering Precision Psychiatry:
- Through its advanced biomarker technology, Brainify.AI assists in the identification of optimal patient segments, predicting treatment

Merck Digital Sciences Studio

Merck Digital Science Studio



BRAINIFY. AI

Brainify.Al

responses, and reducing the prevalence of placebo responders — all important to improving



This MDSS acceptance not only empowers our technological advancements but is also a testament to our vision in precision medicine. Being part of MDSS will significantly accelerate our journey."

Mariam Khayretdinova, CEO & co-founder

clinical trials in psychiatry.

Companion Diagnostics Development:

- Brainify.Al's platform extends beyond clinical trials into the development of companion diagnostics, potentially offering a cost-effective and predictive toolset for patienttailored treatment regimens in the fight against mental health disorders.

About Merck Digital Sciences Studio
Merck Digital Sciences Studio (MDS Studio or MDSS) is a
collaboration between Merck, Merck Global Health
Innovation Fund, Northpond Ventures, McKesson
Ventures, Microsoft for Startups, and the New Jersey

Innovation Institute, a New Jersey Institute of Technology (NJIT) subsidiary. The 10-month startup accelerator program, with direct investments from Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures, empowers members and enables the generation of innovative digital technologies for drug discovery and development through hands-on mentorship, connection opportunities with industry-leading partners, and training in an active entrepreneurial setting. Through the accelerator program, these startups will have access to workshops, coaching, office space, and Microsoft for Startups Founders Hub resources, including up to \$150,000 Azure Cloud computing credits.

About Brainify.Al

Brainify.AI (https://www.brainify.ai), J&J JLabs resident, is a groundbreaking company pioneering the shift toward precision psychiatry. Brainify.AI leverages biological data through the innovative AI EEG biomarker platform. Brainify.AI transformative technology and cutting-edge tools are setting new standards in the psychiatric field, bridging the gap between clinical trials and effective treatments, thus catalyzing a new era of precision psychiatry.

Ivan Mishanin
Brainify.AI
+1 855-712-1818
email us here
Visit us on social media:
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/671360254

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.		